Why We Do What We Do
Our commitment to our patient communities is about responsibility.
Responsibility to seek innovation, to understand the challenges faced by patients and their families, to communicate with them clearly and openly and ultimately to develop medicines that transform their lives.
Life with Angelman Syndrome: Coming to Terms with the Diagnosis
An Angelman syndrome diagnosis can be extremely impactful on a family, changing their future. Hear how one family is embracing each day with hope thanks to help from their friends and local community.
Life with Angelman Syndrome: Challenging Conversations
Motor and communication skills are often severely impacted by Angelman syndrome, making it challenging to communicate even the most basic needs.
Life with Angelman Syndrome: Maintaining Hope
Between managing sleep deprivation at night and overstimulation during the day, Angelman syndrome takes toll on those with the condition and their families.
“Rhys loves everyone unconditionally. He can make anyone smile, especially on the days you need it most. He has a heart of gold.”
– Rob & Melissa, Rhys’ parents
“Kyla’s smiles, sense of humor, perseverance, and strength have reminded us to find joy in the journey. She does not give up, and neither will we.”
– John, Kyla’s dad
“Cody has a heart of gold that always finds the good in life and people. He does not judge, he is non-materialistic and he has a love for life that is very infectious.”
– Claire, Cody’s mom
“We work harder, care greater, love deeper, and hug longer. This life is not a pass/fail test, rather than a challenge of endurance.”
– Arianna’s mom
“Nathan is an absolute joy to everyone he meets. Some of his favorite things include balloons, airplanes, and anything with water.”
– Nathan’s parents
“Everyone’s not perfect, and everybody is different in their own way.”
– Reagan, Maggie’s cousin
“Happy is the man who has broken the chains
which hurt the mind, and has given up worrying
once and for all. Be patient and tough; one day
this pain will be useful to you.”
– Ovid, Metamorphoses
OV101 Clinical Trials
Phase 2 Stars Trial
Working with foundations focused on Angelman syndrome, we designed the Phase 2 STARS study, the first industry-sponsored, international, randomized, double-blind, placebo-controlled clinical trial in adults and adolescents with Angelman syndrome. STARS investigated safety parameters as well as exploratory efficacy endpoints. In October 2018, Ovid announced comprehensive data from the STARS trial at the American Academy of Child & Adolescent Psychiatry’s 65th Annual Meeting. The trial met its primary endpoints of safety and tolerability and also showed a statistically significant improvement compared to placebo in the clinican-rated clinical global impression of improvement (CGI-I) – a common measure that allows the clinician to capture a constellation of clinical symptoms.
Ovid Therapeutics also plans to initiate the ELARA trial, an open-label extension study that will enable individuals with Angelman syndrome who completed any prior OV101 study to be eligible to receive the investigational medicine. The study will use once-daily dosing and will assess long term safety and tolerability in addition to efficacy measures.
Learn more about Angleman syndrome
Phase 2 ROCKET Trial
The Phase 2 ROCKET trial is a three-arm, double-blind, clinical trial designed to evaluate the safety and tolerability of OV101 in adolescent and young adult males, aged 13 to 22, who have been diagnosed with Fragile X syndrome. In addition to safety, the study will also assess changes in behavior during 12 weeks of treatment with OV101. Ovid Therapeutics is currently enrolling patients in the ROCKET trial.
Ovid Therapeutics also initiated SKY ROCKET, a non-drug study to assess the suitability of scales for the measurement of behavior, sleep and functioning in individuals with Fragile X syndrome. This trial is designed to provide additional data on the key endpoints that are being explored in ROCKET and provide comparative data on the benefit offered by the standard of care. The study will enroll 30 males ages 5 to 30 with Fragile X syndrome.
OV935 Clinical Trials
Phase 1b/2a Trial in Rare Epilepsies
OV935 is currently in development for the treatment of certain types of rare epilepsies. The Phase 1b/2a randomized, double-blind, clinical trial is designed to look at the safety, tolerability, PK, and pharmacodynamics of OV935 in adult patients with rare developmental and epileptic encephalopathies. Developmental and epileptic encephalopathies are a group of rare epilepsies that include syndromes such as Dravet syndrome, Lennox-Gastaut syndrome, and Tuberous Sclerosis Complex. Enrollment of the trial is complete and Ovid Therapeutics expects to announce study data in the fourth quarter of 2018.
Phase 2 ARCADE Trial
The Phase 2 ARCADE trial is a multi-center, open-label, pilot study designed to evaluate OV935 in patients, aged 2 to 17 years old with CDKL5 deficiency disorder or Dup15q syndrome. This study is designed to assess the frequency of motor seizures in patients treated with OV935, as well as the safety, tolerability and PK of OV935. Ovid Therapeutics intends to enroll approximately 15 children with each condition. Ovid Therapeutics is now enrolling patients.
Phase 2 ELEKTRA Trial
The ELEKTRA trial is a Phase 2, international, multi-center, randomized, double-blind, placebo controlled, parallel-designed study designed to investigate OV935 in patients aged 2 to 17 years old with Dravet syndrome or Lennox-Gastaut syndrome. The study will evaluate the frequency of seizures in patients treated with OV935 compared to placebo, as well as the safety, tolerability and PK of OV935. Approximately 125 patients will be randomized to receive either OV935 or placebo. Ovid Therapeutics is now enrolling patients.
Open to all patients who have participated in a previous OV935 clinical trial, the ENDYMION trial is an open-label, extension study which will assess long term-safety and tolerability of OV935 in patients with rare epilepsies over a course of two years. The study will also evaluate the effect of OV935 on seizure frequency during the same time period. ENDYMION started to enroll patients in the third quarter of 2018.
Expanded Access Program (EAP)
The Ovid team is driven by the passion to improve the lives of patients and caregivers by working to develop new medicines for people living with rare and serious illnesses. As a company, we want to bring our medicines to the largest numbers of people who may potentially benefit from them. At the same time, we have a duty to balance this desire while ensuring that our investigational drugs are both safe and effective before making them available outside of the controlled setting of a clinical trial.
We understand that individuals with Angelman syndrome do not have many options to address their medical needs. Investigational clinical trials are the fastest path to bring forward a potential treatment for Angelman syndrome. Because our goal is to help as many patients as possible, as quickly as possible, access to the investigational therapy outside of a clinical trial must not adversely impact or delay the clinical trials involving the investigational therapy.
At times a health care provider may seek access to an unapproved drug candidate for a patient with a life threatening or serious disease who has exhausted all medical options. This use of a drug candidate outside of the context of a clinical trial is called expanded access, among other names. Currently, Ovid is evaluating the potential for an expanded access program for OV101 and will work with regulators to determine the best path forward.
The following is additional information regarding Ovid’s expanded access policy in accordance with the 21st Century Cures Act:
- Contact Information. If you have any questions regarding Ovid’s expanded access policy in general, please contact firstname.lastname@example.org. If you have any questions regarding potential participation in Ovid’s clinical trials, please contact us by email at email@example.com.
- General Criteria. If Ovid opens an expanded access program, we will update this policy and provide appropriate details.
- Response Timing. If you contact Ovid as described above, we anticipate that we will acknowledge receipt within five business days.